Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hirotoshi Kakuta
Observed names:
H Kakuta,
Hirotoshi KAKUTA
Institution:
Astellas Pharma (Japan)
Observed institutions:
Astellas Pharma (Japan),
University of Tsukuba,
University of the Ryukyus,
Shizuoka General Hospital
OpenAlex ID:
A5011693789
Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
2005
·
H Kakuta
, K Sudoh
, et al.
·
PubMed
·
140
YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species
2000
·
Tohru Ugawa
, Hirotoshi Kakuta
, et al.
·
British Journal of Pharmacology
·
82
PDF
Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques
2012
·
Akihiro Noda
, Hiroshi Fushiki
, et al.
·
Nuclear Medicine and Biology
·
51
Effects of Atorvastatin on Glucose Metabolism and Insulin Resistance in KK/Ay Mice
2005
·
Masatsune Suzuki
, Hirotoshi Kakuta
, et al.
·
Journal of Atherosclerosis and Thrombosis
·
46
PDF
Assembly of Lipoprotein (a) in Transgenic Rabbits Expressing Human Apolipoprotein (a)
1999
·
Jianglin Fan
, Masahiro Araki
, et al.
·
Biochemical and Biophysical Research Communications
·
39
Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor
2010
·
Kazuki Ohno
, Yasushi Amano
, et al.
·
Biochemical and Biophysical Research Communications
·
37
Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors
2003
·
Tsukasa Ishihara
, Hirotoshi Kakuta
, et al.
·
Bioorganic & Medicinal Chemistry
·
32
Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses
2014
·
Hirotoshi Kakuta
, Eiji Kurosaki
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
27
Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors
2004
·
Tsukasa Ishihara
, Hirotoshi Kakuta
, et al.
·
Bioorganic & Medicinal Chemistry
·
23
Synthesis and Biological Evaluation of Quinuclidine Derivatives Incorporating Phenothiazine Moieties as Squalene Synthase Inhibitors
2004
·
Tsukasa Ishihara
, Hirotoshi Kakuta
, et al.
·
Chemical and Pharmaceutical Bulletin
·
23
PDF
YM‐53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents
2003
·
Tohru Ugawa
, Hirotoshi Kakuta
, et al.
·
British Journal of Pharmacology
·
22
Effect of YM‐53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters
2002
·
Tohru Ugawa
, Hirotoshi Kakuta
, et al.
·
British Journal of Pharmacology
·
18
PDF
Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor
2002
·
Toshiyuki Funatsu
, Hirotoshi Kakuta
, et al.
·
European Journal of Pharmacology
·
17
Experimental model of escape phenomenon in hamsters and the effectiveness of YM‐53601 in the model
2002
·
Tohru Ugawa
, Hirotoshi Kakuta
, et al.
·
British Journal of Pharmacology
·
16
PDF
Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model
2003
·
Toshiyuki Funatsu
, Hirotoshi Kakuta
, et al.
·
Metabolism
·
15
Pharmacological Properties of YM17E, an Acyl-CoA: Cholesterol Acyltransferase Inhibitor, and Diarrheal Effect in Beagle Dogs
1997
·
Makoto Kashiwa
, Yoichi Masuyama
, et al.
·
The Japanese Journal of Pharmacology
·
15
Syntheses of 3-Ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels
2003
·
Tsukasa Ishihara
, Hirotoshi Kakuta
, et al.
·
Bioorganic & Medicinal Chemistry
·
11
Atorvastatin (Lipitor®): a review of its pharmacological and clinical profile
2001
·
Toshiyuki FUNATSU
, Hirotoshi KAKUTA
, et al.
·
Folia Pharmacologica Japonica
·
9
PDF
Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat
2015
·
Keiichi Taniguchi
, Hirotoshi Kakuta
·
European Journal of Pharmacology
·
8
Pharmacological and clinical profile of bixalomer (Kiklin^|^#174; capsules): a new therapeutic agent for hyperphosphatemia
2013
·
Keiichi Taniguchi
, Hirotoshi Kakuta
, et al.
·
Folia Pharmacologica Japonica
·
2
PDF
An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-Ay Diabetic Mice
2006
·
Hirotoshi Kakuta
, Toshiyuki Takasu
, et al.
·
International Journal of Biomedical Science
·
2
An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
2008
·
Hirotoshi Kakuta
, Katsumi Sudoh
, et al.
·
Vascular Disease Prevention
An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
2007
·
Hirotoshi Kakuta
, Katsumi Sudoh
, et al.
·
Vascular Disease Prevention
Transgenic Rabbits: A Novel Model for the Study of Atherosclerosis
2005
·
Jianglin Fan
, Masahiro Araki
, et al.
·
Kluwer Academic Publishers eBooks
Synthesis and Biological Evaluation of Quinuclidine Derivatives Incorporating Phenothiazine Moieties as Squalene Synthase Inhibitors.
2005
·
Tsukasa Ishihara
, Hirotoshi Kakuta
, et al.
·
ChemInform
Show more works
View as search
Works count:
26
Citation count:
635
H-index:
15
I10-index:
17
Year
Topic
Type
